Incyte

Yahoo Finance • yesterday

Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding

Winnie partners with Incyte to raise awareness of vitiligo WILMINGTON, Del., December 02, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced its partnership with world renowned supermodel and beauty entrepreneur Winnie Harlow — o... Full story

Yahoo Finance • 11 days ago

Goldman's 20 S&P 500 stocks with most concentrated hedge fund ownership ranked by SA Quant

[Close Up Shot of a Computer Monitor Screen with Real-Time Stocks, Commodities and Exchange Market Charts and Tickers on a Multi-Display Workstation in a Financial Business Office.] gorodenkoff Goldman Sachs analysts updated their basket... Full story

Yahoo Finance • 12 days ago

LLY joins $1T club but doesn't feature in SA's top 10 large-cap healthcare stocks

[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) officially joined the elite group of U.S. companies valued at more than $1T on Friday, becoming the tenth American... Full story

Yahoo Finance • 15 days ago

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valu... Full story

Yahoo Finance • 15 days ago

Vitiligo Market Analysis Report 2025-2035: Targeted Therapies Like Biologics, Oral Medications, and Advanced Topicals Bolster Growth

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. T... Full story

Yahoo Finance • 19 days ago

Cold Agglutinin Disease (CAD) Market Analysis, Business Prospects, Case Studies and Competitive Intelligence 2025-2035

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Cold Agglutinin Disease Market - A Global and Regional Analysis: Focus on Drug Class, Dosage Form, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's... Full story

Yahoo Finance • 23 days ago

Cathie Wood's Ark Invest weekly moves: Adds to ACHR and CRSP, trims positions in ROKU and SOFI

[Wooden Blocks with ETF Letters Surrounded by Coins and Financial Icons Representing Investment Growth and Financial Strategies in a Modern Finance Context] Suphachai Panyacharoen Cathie Wood’s ARK Invest reshuffled its portfolio this wee... Full story

Yahoo Finance • 24 days ago

Notable healthcare headlines for the week: Pfizer, Novo Nordisk, Moderna in focus

Wall Street major averages posted weekly loses amid an AI-tech trade that continued to struggle, with lower consumer sentiment, and the ongoing U.S. government shutdown. Week to date, the Nasdaq and S&P 500 were down 3% and 1.6%, respecti... Full story

Yahoo Finance • 27 days ago

Is It Time to Reevaluate Incyte After Strong Pipeline Update and 52% Price Surge?

Wondering whether Incyte is priced right, or if the market is missing something? You're not alone. This is one biotech that has investors talking about value. The stock has surged 17.2% in just the past week, racking up a 52.0% gain year-t... Full story

Yahoo Finance • last month

United States Vitiligo Market Research Report 2025-2033 by Diseases Type, Treatment Type, End User, Regions and Company Analysis

Company Logo The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improv... Full story

Yahoo Finance • last month

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del., October 30, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monda... Full story

Yahoo Finance • last month

Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the reg... Full story

Yahoo Finance • last month

Thérapeutique Knight annonce l'approbation et le lancement de MINJUVI® (tafasitamab) en Argentine

MONTRÉAL, 30 oct. 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd'hui que sa filiale argentine, Laboratorio LKM S.A. a obt... Full story

Yahoo Finance • last month

Bank of America Securities Maintains a Buy on Incyte Corporation (INCY)

Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on October 22, setting a price target of $104... Full story

Yahoo Finance • last month

Morning Bid: Gold sold, stocks stall

By Mike Dolan -What matters in U.S. and global markets today By Mike Dolan, Editor-At-Large, Finance and Markets As U.S. stock indexes hit new records on Monday ahead of a likely Federal Reserve interest rate cut and megacap earnings la... Full story

Yahoo Finance • last month

Incyte Q3 25 Earnings Conference Call AT 8:00 AM ET

(RTTNews) - Incyte Corporation (INCY) will host a conference call at 8:00 AM ET on October 28, 2025, to discuss Q3 25 earnings results. To access the live webcast, log on to https://Investor.Incyte.com To listen to the call, dial 877-407... Full story

Yahoo Finance • last month

Incyte (INCY): Evaluating Valuation as Baricitinib Advances Toward Expanded Approval for Adolescent Alopecia Areata

New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals for expanded use based on these results... Full story

Yahoo Finance • last month

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in a... Full story

Yahoo Finance • last month

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show 71% of adolescents with severe disease... Full story

Yahoo Finance • 2 months ago

Xencor Stock Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Xencor shows improving technical performance. Will it continue? Continue Reading View Comments... Full story